ERBB2 and Obesity: This trend is attributed to advancements in cancer treatment, the associated increased CV risk linked to these therapies (e.g., anthracyclines, anti HER2 monoclonal antibodies, chest radiotherapy), overlapping initial risk factors (e.g., obesity, physical inactivity, alcohol consumption), and insufficient CV follow-up in women [35].